Home » Stocks » PCSA

Processa Pharmaceuticals, Inc. (PCSA)

Stock Price: $10.77 USD 0.12 (1.13%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $10.74 -0.03 (-0.28%) Mar 5, 5:38 PM
Market Cap 113.79M
Revenue (ttm) n/a
Net Income (ttm) -5.45M
Shares Out 5.59M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $10.77
Previous Close $10.65
Change ($) 0.12
Change (%) 1.13%
Day's Open 10.79
Day's Range 9.95 - 11.15
Day's Volume 114,458
52-Week Range 3.40 - 13.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional a...

Newsfile Corp - 1 week ago

Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available here ...

Seeking Alpha - 1 month ago

Experienced management team with colossal past exits running 3 active mid-stage clinical programs with enough funding to generate progress through multiple value-inflection points. PCS499: Ulc...

GlobeNewsWire - 1 month ago

HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to ...

About PCSA

Processa Pharmaceuticals, a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibi... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Dr. David Young
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
PCSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PCSA stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 25.35% from the latest price.

Price Target
$13.50
(25.35% upside)
Analyst Consensus: Strong Buy